NDAINJECTIONINJECTABLE
Approved
Aug 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RAPLON (rapacuronium bromide) is an injectable neuromuscular blocking agent used during anesthesia to facilitate intubation and surgical procedures. It is a rapid-onset, short-duration depolarizing agent that works by binding to nicotinic acetylcholine receptors at the neuromuscular junction. This product enables rapid airway management in perioperative settings.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely transitioning to defensive strategies and cost optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RAPLON offers limited career advancement opportunities due to its mature lifecycle and approaching LOE, with few linked job openings. Roles focus on defensive market management, pricing optimization, and competitive positioning rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on RAPLON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.